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ABSTRACT 
Severe COVID-19 cases are mostly due to severe inflammatory reaction and cytokine storm, which may lead to multiple organ failure and death. Until 
recently, there is no proven effective treatment for severe COVID-19. Mesenchymal stem cells (MSCs) have anti-inflammatory and regenerative 
properties. Therefore, they are supposed to work on COVID-19, which has failed to recover using other treatments. Therefore, studies are needed to 
determine the best tissue source of MSCs, the dose, repeat, and route of administration. For this review, we searched various databases, i.e. Pubmed, 
Science Direct, Springer, and WHO website using keywords: “mesenchymal stem cells” and “COVID-19” at 7 May 2020, without time limits. Various 
clinical trials on the use of MSCs for COVID-19 were registered, and initial results were reported. Initial results were promising but should be interpreted 
cautiously, as one was a case report, another one was case series, and one was a preliminary study of seven treated patients compared to three controls, 
where the baseline conditions were unequal. Therefore, well design randomized clinical trials are needed to get more robust prove. 
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INTRODUCTION 
The first pneumonia case, which was presumably due to a novel 
Coronavirus, was identified in Wuhan, China on 14 November [1], 
but cases were communicated to WHO on 31 December 2020 as 
pneumonia of unknown cause [2]. On 27 December, three patients, 
who were ill for four to seven days, were admitted to a hospital in 
Wuhan, and on 30 December their broncho-alveolar-lavage samples 
were collected. RNA extraction, direct PCR, whole-genome 
sequencing, and virus isolation from the lavage samples showed the 
presence of a new betacoronavirus with more than 85% similarity to 
a bat SARS-like CoV (bat-SL-CoVZC45, MG772933.1) [3]. The new 
virus, which was previously named 2019 novel coronavirus (2019-
nCoV), is named SARS-CoV-2 and the disease it causes is named 
coronavirus disease (COVID-19) [4]. The new virus infects cells 
through angiotensin-converting enzyme 2 (ACE2) that is present in 
various types of cells including type 2 alveolar cells of lungs, 
stratified epithelial cells of the tongue, oral mucosa, and esophagus; 
columnar epithelial cells of ileum and colon, and myocardial cells. 
Further, to enter a cell, viral S (spike) protein should be primed by 
host cell serine protease TMPRSS2 [5, 6]. COVID-19 spreads very fast 
crossing the borders to other countries, and on 11 March, the WHO 
has declared COVID-19 as a pandemic [7].  
Till to date, there is no proven effective treatment for COVID-19, 
though dozens of existing compounds were suggested to be tested. A 
mega-trial on thousands of COVID-19 confirmed cases, which is 
called Solidarity, is recently underway to test four most promising 
compounds or combinations of compounds [8].  
Around 15% of COVID-19 patients will fall into a severe state that 
makes hospitals become overwhelmed [8], so that many patients are 
neglected and cannot get appropriate treatment. Severe cases are 
mostly due to cytokine storms, which may lead to multiple organ 
failure and death [9], and might be managed by anti-inflammatory 
agents. One of the anti-inflammatory agents is a certain kind of stem 
cells, namely mesenchymal stem cells.  
The main aim of this review is to present a brief outline of the 
properties of stem cells, general properties of mesenchymal stem cells, 
requirement of mesenchymal stem cell use in patients, the theoretical 
justification of mesenchymal stem cell use in COVID-19, and various 
published results and on-going clinical trials on mesenchymal stem 
cell use in COVID-19 to prevent or modulate severe COVID-19.  
For this review, we searched various databases, i.e. Pubmed, Science 
Direct, Springer, and WHO website using keywords: “mesenchymal 
stem cells” and “COVID-19” at 7 May 2020, without time limits. Only 
English literatures were used. In addition, mesenchymal stem cell 
and COVID-19 related articles that were found during the writing of 
this article were included. 
The properties of stem cells 
Stem cells are the origin of all other cells in the body, and have two 
main capacities i.e. self-renewal and differentiation. According to the 
source, there are two main types of natural stem cells, i.e. embryonic 
and adult stem cells. Adult stem cells are more preferred, as their 
use is not restricted by ethical problems [10], and usually does not 
cause teratoma as the use of embryonic stem cells.  
One type of adult stem cells that are widely used is the mesenchymal 
stem cell. Mesenchymal stem cells (MSCs) can be isolated easily from 
various tissues, including bone marrow [11], adipose tissue [12], 
umbilical cord [13], dental pulp [14], etc. Bone marrow MSCs were 
the first studied, followed by adipose tissue, umbilical cord, and 
various other tissues. MSCs from various sources show similar 
properties but may have subtle differences that can be seen in 
different DNA methylation pattern [15].  
General properties of mesenchymal stem cells  
Mesenchymal stem cells should fulfil minimal requirements that were 
set by International Society for Cell Therapy (ISCT), i.e. their shape 
should be fibroblastic, they should adhere to plastic vessel where they 
were cultured and should have certain positive surface markers>95%, 
i.e. CD 73, CD 90 and CD105, and negative surface markers (CD11b, 
CD14, CD19, CD34, CD45, CD79a and HLA-DR) should be<2%. In 
addition, they should be able to differentiate into three lineages, i.e. 
into chondrocyte, osteocyte, and adipocyte lineages [16]. 
The acronym MSCs recently may stand for mesenchymal stem cells, 
mesenchymal stromal cells, multipotent stem cells, or medicinal 
signaling cells. The ISCT, which is now broadened to the International 
Society for Cell and Gene Therapy, has formed an MSC committee that 
supports the use of the acronym MSCs as mesenchymal stem cells with 
certain requirements. The requirements include: the naming should be 
followed by an explanation of the tissue source, stemness should be 
proven in vitro and in vivo, and functional assays are needed to 
demonstrate MSC properties that are related to the intended 
therapeutic use of the MSCs [17]. 
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MSC properties that are related to therapeutic use are secretion of 
trophic factors that may help in regeneration of injured tissue/organ, 
immunomodulation and promotion of angiogenesis. The assays to 
prove those properties, which are recommended by the ISCT’s MSC 
committee, include quantitative RNA analysis of a certain gene, flow 
cytometry to prove the presence of surface markers, MSC secretome 
protein analysis, and characterization of MSC exosomes and their 
contents including microRNAs (miRNAs) [17]. 
Requirement of mesenchymal stem cell use in patients 
To be used in patients, US Food and Drug Administration (FDA) has 
set a regulation that MSC production should be done in a current 
Good Manufacturing Practice (cGMP) facility to ensure that the 
product is safe and sterile, and following current Good Tissue 
Practice (cGTP) to prevent transmission of diseases from donors. In 
addition, various additional testing, including sterility, mycoplasma 
and endotoxin test should be conducted [18], and when post-thawed 
MSCs are used, viability should be ≥70% (FDA) or ≥ 80% (European 
Medicines Agency [EMA]) [19, 20]. To prevent zoonotic infectious 
agents and immune reaction due to xeno-material use, animal free 
material usage is encouraged, and to ensure efficacy, early passage 
use (passage-3 to passage-7) is recommended [20].  
Theoretical justification of stem cell use in COVID-19 
In severe COVID-19, patients may develop a severe inflammatory 
reaction and cytokine storm that causes acute respiratory distress 
syndrome (ARDS) and/or multiple organ failure, which finally leads to 
death [9]. Various studies showed the safety and efficacy of 
mesenchymal stem cells either against various inflammatory 
conditions, such as diseases with underlying inflammatory reactions, 
or conditions that needs immunomodulation [21]. Mesenchymal stem 
cells are immune-privileged as they have very few or negative class II 
human leucocyte antigen (HLA-II/HLA-DR)/major histocompatibility 
complex (MHC) class II, and co-stimulatory CD80 and CD86 molecules 
that are required for Т-lymphocyte activation, so that allogeneic MSCs 
might not be rejected. They also have immunosuppressant and anti-
inflammatory properties. MSCs are attracted to site of inflammation, 
where they interact with immune cells and cause a shift in cytokine 
profile from inflammatory to anti-inflammatory profile [22]. Moreover, 
MSCs communicate with cells in injured tissues and secrete trophic 
factors that are needed for tissue repair [23]. Therefore, it is supposed 
that MSCs may prevent or modulate severe inflammatory reactions, 
and may promote repair in the injured lung due to COVID-19. 
However, there are some matters that need to be solved, such as the 
dose and route of administration and tissue source of the MSCs.  
MSCs against various inflammatory or autoimmune diseases 
Various diseases have underlying inflammatory or autoimmune 
reaction, such as inflammatory bowel disease in the form of perianal 
fistula in Crohn’s disease and ulcerative colitis; multiple sclerosis, 
systemic lupus erythematosus, graft versus host disease, inflammatory 
lung disease, type-1 and type-2 diabetes mellitus, etc. MSC 
immunomodulation properties have been used to treat those diseases, 
using various MSC sources, various doses, and various route of 
administration with variable degrees of success, but showed no long 
lasting effect, as improvement is usually temporary and last between 
six months to one year. This temporary effect might be due to the 
characteristics of treated diseases that were mostly chronic in nature 
[24-26]. COVID-19 is not a chronic disease, thus the use of MSCs that is 
intended to alleviate the cytokine storm and inflammatory reaction at 
the moment is justified, as after the inflammation and cytokine storm 
subsided MSCs are not needed any more. 
Most MSC therapy, which used hospital-based-laboratory grown 
MSCs, for graft versus host disease, showed good results, but a large 
phase III study, which used commercial industrial product 2x106 
cells/kg body weight, twice a week for four weeks, failed to reach its 
primary clinical endpoint. This failure was supposed to be due to 
over-expanded MSCs that were directly used after thawing [27]. 
Therefore, for COVID-19, the MSCs should meet the requirements 
that were set by US-FDA or EMA [18-20]. In addition, when 
cryopreserved MSCs were used, re-culture to regain their immune-
modulatory property is recommended. 
Dose and route of administration 
Previous studies on MSC use in diseases with underlying inflammatory 
or autoimmune reactions showed that those studies used various MSC 
sources, doses and routes of administration [24-26]. Therefore, MSC 
use in COVID-19 might take advantage from the knowledge of optimal 
and safe doses of MSC from a certain source. As the use of MSCs is 
intended to alleviate ARDS due to cytokine storm, the optimal route is 
supposed to be intravenous. A tracing study in mice, which used in 
vivo imaging system, revealed that 24 h after injection, most of the 
MSCs will be trapped in the lungs (30-60%), and liver (5-15%) [28]. A 
study on the clinical trial. Gov from 2008 through 2018, which 
consisted of 914 MSC trials, showed that 43 % used the intravenous 
(IV) route. From the 914 trials, 16 had published their results. Most of 
the 16 published results showed that improved outcomes were 
attained using minimal effective dose (MED) between 70—190 million 
MSCs/patient/dose for IV route. However, four trials, which reported a 
dose response data, showed a narrower MED of 100-150 million 
MSCs/patient, while higher or lower IV doses were less effective [29]. 
A more direct route, such as on site transplantation into the bronchial 
tree and alveoli, theoretically may place the MSCs in the real battle 
field, but the fact that in ARDS there is accumulation of proteinaceous 
and fibrin exudate inside alveoli, and abundant macrophages 
infiltrating air spaces [30], this approach may be counterproductive as 
the MSCs may stay in the lumen of bronchial tree and cannot reach the 
battle field. Moreover, vehicle solution to suspend the MSCs may 
prevent oxygenation in alveoli, and aggravate the condition. 
Tissue source of MSCs 
Immune modulation property of MSCs might cope with severe 
inflammatory reaction in the lungs or other affected organs, and may 
mitigate the cytokine storm. In addition, MSC capacity to secrete 
trophic factors may aid in regeneration of injured tissues/organs. 
MSCs can be taken from various tissues, but for immune-modulatory 
purposes, MSCs from bone marrow (BM-MSCs), adipose tissue (AT-
MSCs) and birth-related tissue, namely umbilical cord MSCs (UC-
MSCs), umbilical cord blood MSCs (UCB-MSCs) are usually used in 
clinical trials [31]. Therefore, the most appropriate source need to be 
determined. Autologous MSCs need to be isolated and cultured to 
attain a certain number that is needed, thus need time around three to 
four weeks to be ready. As COVID-19 patients with ARDS needs fast 
management, ready to use allogeneic MSCs are more appropriate.  
Bone marrow MSCs are the first studied and used in many clinical 
trials, but bone marrow aspiration is painful and may pose risks to 
the donor. Moreover, a study reviewed the immune-modulatory 
properties of MSCs from various tissues and showed that AT-MSCs 
had stronger immune-modulatory property compared to BM-MSCs, 
while UC-MSCs were similar to BM-MSCs, in term of inhibiting 
CD4+/CD8+lymphocyte activation. In term of dendritic cell 
differentiation inhibition, AT-MSCs showed more profound effect 
compared to BM-MSCs, and in term of dendritic cell maturation 
inhibition, UC-MSCs were equal to BM-MSCs, but UC-MSCs showed 
stronger effect in reducing dendritic cell endocytotic ability 
compared to BM-MSCs. In term of cytokine release inhibition, UCB-
MSCs were the most potent [31]. However, the isolation of UCB-
MSCs is the most difficult compared to UC-MSCs or AT-MSCs. 
Therefore, studies are needed to determine the best tissue source of 
MSCs, the dose, repeat, and route of administration. 
Various on-going clinical trials on stem cell use in COVID-19 and 
a published result 
A search in WHO International Clinical Trials Registry Platform 
(ICTRP) [32] on 26th March 2020 for COVID-19 yielded 648 clinical 
trials, twenty-eight of which are using MSCs, MSC’s product (exosome 
and conditioned medium) or MSCs combined with other type of 
therapy. The clinical trials were registered in ClinicalTrial. Gov (nine 
trials [clinical trial identifier: NCT]), and Chinese Clinical Trial Registry 
(nine teen Trials [clinical trial identifier: ChiCTR]); mostly were from 
China (twenty-six), one from Jordan and one from Brazil. Four out of 
the registered clinical trials in Chinese Clinical Trial Registry were 
cancelled by the investigator and one that was registered in clinical 
trial. Gov was withdrawn. Most of the clinical trials used UC-MSCs, and 
were mostly given by intravenous route. The dose was variable, and 
given once to five times. However, the age ranges of most trials were 
very broad (table 1). These broad age ranges and simple 
randomization may result in unequal baseline age characteristics, so 
that the control and treatment group will not be comparable. 
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One of the clinical trials that used MSCs for COVID-19 pneumonia 
(ChiCTR2000029990), which intended to enroll 60 MSC treated 
subjects and 60 controls (table 1), has published part of the study. 
This report by Leng et al. [33] enrolled seven MSC treated subjects 
and three controls and showed promising results in term of clinical 
recovery and serum cytokine profile. The MSCs were given only once 
intravenously, 106 cells/kg body weight; all of the critically severe, 
severe, and common type of COVID-19 in the treatment group 
recovered, while none of the control group, which were all of the 
severe type, recovered. In the control group, one died, one 
developed ARDS, and one remains stable. However, the treatment 
and control groups were unequal in term of their age and severity of 
the disease. The treatment group consisted of one critically severe, 
four severe and two common, while the control group consisted of 
three severe types of COVID-19, which means that the treatment 
group was more variable compared to the control group. Moreover, 
the ages of patients were not equal; the control group, who died and 
the one that developed ARDS, were much older than in the treatment 
group. The oldest patient in the treatment group, who had a 
critically severe type, was 65 y old, while the patients in the control 
group, who died and developed ARDS, were 75 and 74 y old, 
respectively [33]. A study on 1099 confirmed COVID-19 patients 
showed that subjects of ≥ 65 y old were more prone to end in ICU, 
needed mechanical ventilation or death compared to those of at 
younger ages, which were 49.2%, 32,3, 18.5, and 0% for patients 
aged ≥ 65, 50-64, 15-49, and 0-14 y old, respectively [34]. Another 
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study showed that of 168 deaths due to confirmed COVID-19, 161 
patients were older than 50 y old, and median age was 70 
(interquartile range= 64-78) [35]. In addition, the MSCs in Leng et al. 
study was certified by Chinese FDA (authorization number: 
2004L04792, 2006L01037, CXSB1900004), but the study did not 
mention the tissue source, method of isolation and culture, passage 
or cumulative population doublings, and properties of the MSCs. 
They only mention that the MSCs were ACE2 and TMPRSS2 negative, 
thus could not be infected by the virus, [33]; ACE2 low/negative 
expression is a property that is supposedly shared by most stem 
cells, which are undifferentiated cells, as ACE2 expression depends 
on cell differentiation state [36]. The information concerning tissue 
source, method of isolation and culture, passage or cumulative 
population doubling are necessary, as they may interfere with MSC 
quality and properties [15]. The MSCs in Leng et al. study were 
apparently derived from the umbilical cord, as stated by Zhao that 
MSCs with Chinese FDA authorization number 2004L04792, 
2006L01037, CXSB1900004 were derived from umbilical cords that 
were obtained from two healthy donors and processed in a cGMP 
facility. The cord tissues were processed using collagenase 1 and 
trypsin, and cultured using fetal bovine serum-containing medium, 
and cells from passage-6 were used for transplantation [37]. 
Further, a case report on COVID-19, which was published in 
Chinaxiv. org, showed recovery of a critically ill 65-year-old female 
COVID-19 patient, after three sessions of allogeneic human UC-MSC 
(5x107 cells) and thymosin α1 infusion that were given three days 
apart. Initially, the patient got glucocorticoid, antiviral and antibiotic. 
Then, thymosin α1 was given to modulate immune cell ratio six days 
before UC-MSC, as immune/inflammation-related hemolysis was 
suspected due to failure to increase red blood cell 
count/haemoglobin concentration after blood transfusion. Before 
UC-MSC administration, the patient was in ICU and confirmed as 
critically ill COVID-19 with severe pneumonia, respiratory distress, 
liver injury, type-2 diabetes, hypertension, electrolyte imbalance, 
and acute gastrointestinal bleeding (possibly due to glucocorticoid 
therapy to alleviate inflammatory reaction), thus glucocorticoid was 
stopped before UC-MSC administration. Two days after the last 
session of UC-MSC and thymosin α1, the patient was out of ICU, 
clinical signs and laboratory indices were normal, and swab test was 
reported negative and remained negative 2 d later [38].  
Initial clinical trial results triggered big pharmaceuticals to develop 
clinical trials using their commercial MSC products and attempted to 
get US FDA approval for emergency Investigational New Drug (IND) 
application. ‘Mesoblast Limited’ got an approval on 5 April 2020 for 
Ryoncil (Remestemcel-L) to be used in COVID-19 ARDS. They 
conducted case series, and claimed that 75% of the twelve patients, 
who were previously refractory to other experimental therapies, 
were free from ventilators within 10 d, and overall, there was 83% 
survival after two intravenous infusion of Ryoncil. For comparison, 
Mesoblast used data from two major referral hospital networks in 
New York City, where 9% of 445, and 12% of 320 ventilator 
dependent COVID-19 patients survived when treated with standard 
of care during March and April 2020 [39]. In the future, other MSC 
producing pharmaceutical companies like Athersys, ‘Pluristem 
therapeutics’ with its PLX cell product, Cynata with its Cymerus™ 
platform, ‘Lattice Biologics’ with its AmnioBoost, ‘Tianhe Stem Cell 
Biotechnologies’ and ReeLabs are likely to pursue the same path as 
‘Mesoblast Limited’.  
Finally, theoretically, MSC immunomodulation property might be 
beneficial to alleviate severe inflammation and cytokine storm, but 
immune suppression might also promote secondary infection. 
Therefore, concomitant antibiotic use might be needed. An initial 
case report [38], case series [39] and a small clinical trial [33] seem 
to support the benefit of MSCs to cure severe COVID-19. However, 
those results should be interpreted cautiously, because there were 
severe and critically severe COVID-19 that were able to survive; so 
survival of the patients in the case report and case series might 
reflect the natural course of the disease that in some cases were not 
fatal. A study showed that cumulative risk to primary composite 
end-point events, which were admission to an intensive care unit 
(ICU), mechanical ventilation use, or death, among severe COVID-19 
cases was 20.6% [34]; so, there is around 80% possibility that a 
severe case to be stable or finally recovered and cured. Moreover, 
the shift in pro-inflammatory to anti-inflammatory cytokine profile 
as reported by Leng et al. [33] might reflect the natural course of a 
disease recovery, as shift in cytokine profile also occurred in 
recovered patients without MSC therapy [40]. Therefore, though 
initial study results seem promising, more robust proof is needed, 
and the real prove should come from well design randomized 
clinical trials with enough participants, where randomization will 
assure equality between treatments and controls at baseline.  
CONCLUSION  
Several studies showed that MSCs seemed promising to alleviate 
inflammation and cytokine storm in severe COVID-19, but the 
results should be interpreted cautiously, and well design 
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